Cambridge Healthtech Institute’s Inaugural

Immuno-Oncology Clinical Trials Strategy and Execution

Improving Clinical Success Rates for IO Agents and Combinations

June 18-19, 2019


Recent advances in immuno-oncology (IO) and regulatory approvals of several new agents have led to a spike in the number of IO clinical trials. There are specific limitations in clinical development in IO such as treatment of patients not sufficiently represented in clinical trials, uncertainty of the optimal treatment dosing and duration, and lack of understanding regarding long-term immune related toxicities and atypical tumor responses. Moreover, combination immunotherapy brings additional levels of complexity and requires novel approaches to trial design and execution. Cambridge Healthtech Institute’s Inaugural Immuno-Oncology Clinical Trials Strategy and Execution conference is designed to bring together clinical research executives from biopharma companies and CROs, leading academic PIs, and regulatory experts to discuss the next generation of IO clinical trials.

Keynote Presentation: Clinical Trials for Keytruda and Combinations

Emmett Schmidt, MD, PHD, Associate Vice President, Clinical Oncology, Merck

BASKET TRIALS

ASCO TAPUR Study and Implementing Precision Medicine

Edward S. Kim, MD, Chair, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Donald S. Kim Distinguished Chair for Cancer Research, Atrium Health

ADVANCES IN TRIAL EXECUTION

Digitalization of Clinical Trials in Immuno-Oncology

Jill Loftiss, Head, Clinical Operations & Oncology, MedImmune

REGISTRATION STRATEGIES

Regulatory and Registration Strategies

Chitkala Kalidas, Vice President, Head Oncology Regulatory Affairs, Bayer

The Parker Institute’s Collaborative and Integrated Approach to Immuno-Oncology: Innovative Clinical Trials and Biomarkers

Theresa LaVallee, PhD, Vice President, Translational Medicine and Regulatory Affairs, Parker Institute for Cancer Immunotherapy

PARTNERING ECOSYSTEM IN IO

PANEL DISCUSSION: Partnering, Preclinical Strategies and Tools, IO Clinical Trials; Capital Invested in IO Relative to Other Oncology Areas

Moderator: Leigh Zawel, PhD, CSO, Cullinan Oncology

Panelists: Michael Woo, Director, Head of Immuno-Oncology Search & Evaluation, External Innovation, EMD Serono, Inc.

Sybil Williams, PhD, Director, Biology Oncology Discovery, Merck

Paul Young, PhD, Executive Director, Business Development & Licensing, Merck

Christine Borowski, PhD, Entrepreneur in Residence, Appletree Ventures

  • Has the IO bubble popped? Why have no other IO drugs emerged with PD1/PDL1-like efficacy?
  • What combination strategies are being explored to convert poorly PD1 responsive tumors to more responsive ones?
  • Are there new IO monotherapies or combos that appear promising?
  • Is patient stratification practical with IO therapies?
  • What partnering strategies are most effective?
  • What is a recent deal your firm signed that you’re excited about?

For more details on the conference, please contact:

Marina Filshtinsky, MD
Executive Director, Conferences
Cambridge Healthtech Institute
Phone: 781-972-5496
Email: mfilshtinsky@healthtech.com

For partnering and sponsorship information, please contact:


Companies A-K
Rod Eymael
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-247-6286
Email: reymael@healthtech.com

Companies L-Z

Joseph Vacca, MS
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5431
Email: jvacca@healthtech.com